Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 4, pp 429–437 | Cite as

Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy

  • Robert L. FineEmail author
  • Samir S. Shah
  • Thomas A. Moulton
  • Ing-Ru Yu
  • David R. Fogelman
  • Michael Richardson
  • Howard A. Burris
  • Brian L. Samuels
  • Chatchawin Assanasen
  • Prakash Gorroochurn
  • Hanina Hibshoosh
  • Manuela Orjuela
  • James Garvin
  • Frederick D. Goldman
  • Daniel Dubovsky
  • David Walterhouse
  • Gregory Halligan
Original Article



Desmoplastic small round cell tumor (DSRCT) is a highly fatal, mainly peritoneal cell origin cancer which predominantly affects young adult males. This predilection in young males led us to examine the role of androgen receptors (AR), testosterone, and growth factors in the biology of DSRCT.


Slides were prepared from 27 multi-institutional patients all with end-stage DSRCT. Slides were stained for AR, c-Kit, various growth factors, and drug resistance-associated proteins. Immunohistochemical (IHC) expression was scored semi-quantitatively. Western blot and MTT studies were performed to validate the IHC findings of over-expression of the AR and its functional status by stimulation of growth by dihydrotestosterone, respectively. Six patients with positive AR status were treated solely with combined androgen blockade (CAB) as used for prostate cancer.


Twenty-two patients were male (81%) and five were female (19%) with a median age at diagnosis of 23. All patients had failed at least two prior multi-agent chemotherapy regimens and 44% had progressed after autologous stem cell transplant. DSRCT samples from 10 of 27 patients were ≥2+ IHC positive for AR (37%,P = 0.0045) and 7 of 20 patients were ≥2+ IHC positive for c-Kit (35%, P = 0.018). We found elevated IHC expression of GST-pi, MRP and thymidylate synthase in smaller subsets of patients. In vitro studies for AR by Western blot and stimulation of growth by dihydrotestosterone in MTT assays suggest that the AR in DSRCT cells is functional. Six patients with positive AR status were treated with CAB alone and three of six attained clinical benefit (1-PR, 1-MR, 1-SD) in a range of 3–4 months. The three patients who responded to CAB had normal testosterone levels before CAB, while the three who did not respond to CAB had baseline castrate levels of testosterone.


DSRCT has significant IHC expression of AR and c-Kit in heavily pre-treated patients. The presence of significant AR expression in 37% suggests that these patients could possibly respond to CAB. The significance of c-Kit expression in 35% of DSRCT patients is unknown and warrants further investigation.


Desmoplastic small round cell tumor Androgen receptor Testosterone C-Kit 



This work is dedicated to Ari Kahane who bravely fought and died from DSRCT at age 18. This work was supported in part by the Herbert Pardes Scholar Award, Ari Kahane Memorial Fund, and a grant from Oncotech Inc. to RLF.

Authors’ disclosures of potential conflicts of interest. The following authors or their immediate family members have indicated a financial interest.

Shares Owned: Robert L. Fine, of Oncotech Inc.


  1. 1.
    Gerald W, Miller H, Battifora H et al (1991) Intra-abdominal desmoplastic small round-cell tumor. Amer Surg Path 15:499–513CrossRefGoogle Scholar
  2. 2.
    Bisogno G, Roganovich J, Sotti G et al (2000) Desmoplastic small round cell tumor in children and adolescents. Med Ped Oncol 34:338–342CrossRefGoogle Scholar
  3. 3.
    Roganovich J, Bisogno G, Cecchetto G et al (1999) Paratesticular desmoplastic small round cell tumor: case report and review of the literature. Surg Oncol 71:269–272CrossRefGoogle Scholar
  4. 4.
    Gil A, Portilla A, Brun E et al (2004) Clinical perspective on desmoplastic small round-cell tumor. Oncology 67:231–242PubMedCrossRefGoogle Scholar
  5. 5.
    Kim J, Lee J, Branton P et al (2000) Modulation of EWS/WT1 activity by the v-Src protein tyrosine kinase. FEBS Lett 474:121–128PubMedCrossRefGoogle Scholar
  6. 6.
    Ordonez NG (1998) Desmoplastic small round cell tumor: I: a histopathological study of 39 cases with emphasis on unusual histological patterns. Am Surg Pathol 22:1303–1313CrossRefGoogle Scholar
  7. 7.
    Bertuzzi A, Castagna L, Nozza A (2002) High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 20:2181–2188PubMedCrossRefGoogle Scholar
  8. 8.
    Sandberg A, Bridge J (2002) Updates on the cytogenetics and molecular genetics of tissue tumors: desmoplastic small round-cell tumors. Cancer Gene. Cytogene 138:1–10CrossRefGoogle Scholar
  9. 9.
    Kurre P, Felgenhauer J, Miser J et al (2000) Successful dose-intensive treatment of desmoplastic small round cell tumor in three children. Ped Hemat/Oncol 22:446–450CrossRefGoogle Scholar
  10. 10.
    Zhang P, Goldblum J, Pawel B et al (2003) Immunophenotype of desmoplastic small round cell tumors as detected in cases with EWS-WT1 gene fusion product. Mod Pathol 16:229–235PubMedCrossRefGoogle Scholar
  11. 11.
    Rachfal AW, Luquette M, Brigstock DR (2004) Expression of connective tissue growth factor (CCN2) in desmoplastic small round cell tumor. Clin Pathol 57:422–425CrossRefGoogle Scholar
  12. 12.
    Tuveson D, Fletcher J (2001) Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol 13:249–255PubMedCrossRefGoogle Scholar
  13. 13.
    Kushner B., Laquaglia M, Wollner N et al (1996) Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multi-modality therapy. J Clin Oncol 14:1526–1531PubMedGoogle Scholar
  14. 14.
    Mazuryk M, Paterson A, Temple W et al (1998) Benefit of aggressive multimodality therapy with autologous stem cell transplant support for intra-abdominal desmoplastic small round cell tumor. Bone Marrow Transpl 21:961–963CrossRefGoogle Scholar
  15. 15.
    La Quaglia M, Brennan M (2000) The clinical approach to desmoplastic small round cell tumor. Surg Oncol 9:77–81CrossRefGoogle Scholar
  16. 16.
    Li Y, Mao Y, Brandt-Rauf P, Williams A, Fine RL (2005) Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-JUN-NH2-kinase pathway. Mol Cancer Therap 4:901–909CrossRefGoogle Scholar
  17. 17.
    Kim A, Raffo A, Brandt-Rauf P, Pincus M, Abarzua P, Fine RL (1999). Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human tumor cells. J Biol Chem 274:34924–34931PubMedCrossRefGoogle Scholar
  18. 18.
    Smithey B, Pappo A, Hill D (2002) C-Kit expression in pediatric solid tumors. Am Surg Pathol 26:486–492CrossRefGoogle Scholar
  19. 19.
    Schwarz R., Gerald W, Kushner B et al (1998) Desmoplastic small round cell tumors: prognostic indicators and results of surgical management. Ann Surg Oncol 5:416–422PubMedCrossRefGoogle Scholar
  20. 20.
    Lae ME, Roche PC, Jin L et al (2002) Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am Surg Pathol 26:823–835CrossRefGoogle Scholar
  21. 21.
    Goodman KA, Wolden SL, La Quaglia MP et al (2002) Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumor. Int J Radiat Oncol Biol Phys 54:170–176PubMedCrossRefGoogle Scholar
  22. 22.
    Bertuzzi A, Castagna L, Quagliuolo V et al (2003) Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumor. Br J Cancer 89:1159–1161PubMedCrossRefGoogle Scholar
  23. 23.
    Suehara Y, Yazawa Y, Hitachi K (2004) Intraabdominal desmoplastic small round cell tumor: results of ifosfamide-based chemotherapy. Int J Clin Oncol 9:134–138PubMedCrossRefGoogle Scholar
  24. 24.
    D’Amato G, Steinert DM, McAuliffe JC et al (2005) Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Cont 12:44–56Google Scholar
  25. 25.
    Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet 364:1127–1134PubMedCrossRefGoogle Scholar
  26. 26.
    Rankin C, von Mehren M, Blanke C et al (2004) Dose effect of imatinib in patients with metastatic GIST––a phase III sarcoma group study S0033. Proc Annu Meet Am Soc Clin Oncol 9005 (abstr)Google Scholar
  27. 27.
    Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have Her2overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648PubMedGoogle Scholar
  28. 28.
    Su F, Hu X, Jia W et al (2003) Glutathione-S-transferase pi indicates chemotherapy resistance in breast cancer. J Surg Res 113:102–108PubMedCrossRefGoogle Scholar
  29. 29.
    Welters MJ, Fichtinger-Schepman AM, Baan RA et al (1998) Role of glutathione, glutathione-S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines. Br J Cancer 77:556–561PubMedGoogle Scholar
  30. 30.
    Bennaceur-Griscelli A, Bosq J, Koscielny S et al (2004) High levels of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 10:3029–3034PubMedCrossRefGoogle Scholar
  31. 31.
    Arai T, Yasuda Y, Takaya T et al (2000) Immunohistochemical expression of glutathione-S- transferase-pi in untreated primary non-small cell lung cancer. Cancer Detec Prev 24:252–257PubMedGoogle Scholar
  32. 32.
    Plaat BE, Hollema H, Molenaar WM et al (2000) Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18:3211–3220PubMedGoogle Scholar
  33. 33.
    Kamoshida S, Matsuoka H, Ishikawa T, et al (2004) Immunohistochemical evaluation of thymidylate synthase and p16INK4a in advanced colorectal cancer: Implication of TS expression in 5-FU-based adjuvant chemotherapy. Jpn J Clin Oncol 34:594–601PubMedCrossRefGoogle Scholar
  34. 34.
    Suzuki T, Nisho K, Tanabe S (2001) The MRP family and anticancer drug metabolism. Curr Drug Metab 2:367–377PubMedCrossRefGoogle Scholar
  35. 35.
    Moulton T, Fogelman DR, Thom G, Yu IR, Richardson M, Goldman F, Fruehauf J, Burris H, Fine RL (2003) Desmoplastic small round cell tumor (DSRCT): presence of androgen and c-Kit receptors. Proc Am Soc Clin Oncol 22:802 (abstr)Google Scholar
  36. 36.
    Froberg K, Brown RE, Gaylord H et al (1999) Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Ann Clin Lab Sci 29:78–85PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Robert L. Fine
    • 1
    • 11
    Email author
  • Samir S. Shah
    • 1
  • Thomas A. Moulton
    • 2
  • Ing-Ru Yu
    • 3
  • David R. Fogelman
    • 1
  • Michael Richardson
    • 3
  • Howard A. Burris
    • 4
  • Brian L. Samuels
    • 5
  • Chatchawin Assanasen
    • 6
  • Prakash Gorroochurn
    • 1
  • Hanina Hibshoosh
    • 1
  • Manuela Orjuela
    • 1
  • James Garvin
    • 1
  • Frederick D. Goldman
    • 7
  • Daniel Dubovsky
    • 8
  • David Walterhouse
    • 9
  • Gregory Halligan
    • 10
  1. 1.College of Physicians and Surgeons of Columbia UniversityNew York-Presbyterian Medical Center and Morgan Stanley Children’s HospitalNew YorkUSA
  2. 2.Children’s Hospital at MontefioreBronxUSA
  3. 3.Oncotech Corporation, TustinUSA
  4. 4.Sarah Cannon Cancer CenterNashvilleUSA
  5. 5.Lutheran General HospitalPark RidgeUSA
  6. 6.Nemours Children’s ClinicPensacolaUSA
  7. 7.Children’s Hospital of IowaIowa CityUSA
  8. 8.Atlanta Cancer CareAtlantaUSA
  9. 9.Children’s Memorial HospitalChicagoUSA
  10. 10.St. Christopher’s Hospital for ChildrenPhiladelphiaUSA
  11. 11.Experimental Therapeutics Program, Division of Medical OncologyColumbia University Medical CenterNew YorkUSA

Personalised recommendations